Premium
Effects of a 3‐week moderate calorie restriction intervention on cerebral white matter connectivity in subjects with obesity
Author(s) -
Kahathuduwa Chanaka Nadeeshan,
Davis Tyler,
O'Boyle Michael,
Binks Martin
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.lb279
Subject(s) - fractional anisotropy , fasciculus , medicine , calorie restriction , diffusion mri , obesity , white matter , uncinate fasciculus , superior longitudinal fasciculus , calorie , magnetic resonance imaging , radiology
Objective To examine the effects of a 3‐week 1120 kcal/d calorie restriction intervention on brain structural connectivity (measured using fractional anisotropy; FA) and region‐wise gray matter volumes (GM) in subjects with obesity. Methods Thirty‐two male and female subjects with obesity (19–60 years; 30–39.9 kg/m 2 ) participated in a randomized, two‐group, repeated‐measures, 3‐week dietary intervention consisting of 1120 kcal/d from either total meal replacement (TMR; shakes) or typical diet (TD; portion control). Structural and diffusion tensor MRI were performed pre‐ and post‐intervention. Post‐ vs. pre‐intervention change in FA (ΔFA) and GM (ΔGM) were compared in the whole sample and between groups. Results Fifteen TMR and 13 TD subjects completed the intervention. Post‐ vs. pre‐intervention ΔFA or ΔGM was not significant within each group or between groups. In the whole sample, FA was increased in the right inferior fronto‐occipital fasciculus (IFOF; P = .005, inferior longitudinal fasciculus (P = .015) and uncinated fasciculus (P = .049) in post‐ vs. pre‐intervention comparison. ΔGM was not significant in pooled analysis. Conclusions Calorie restriction for 3 weeks appears to be sufficient to initiate changes in FA. Studies involving longer durations of calorie restriction are needed. Support or Funding Information The study was funded by Nestlé Health Science Inc.